NCT05661201View on ClinicalTrials.gov

NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 12, 2023

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
Solid TumorKRAS Mutation-Related Tumors
Interventions
DRUG

NEROFE

weekly doses of NEROFE (48-288 mg/m2) (dose level 1: 96 mg/m2, dose level -1: 48 mg/m2, dose level 2: 192 mg/m2, dose level 3: 288 mg/m2), intravenously over 60 minutes

DRUG

Doxorubicin

weekly doses of 8 mg/m2 (fixed dose), intravenous push over 3 mins;

Trial Locations (1)

20007

RECRUITING

Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.

All Listed Sponsors
collaborator

Immune System Key Ltd

INDUSTRY

lead

Georgetown University

OTHER